2012-10-12 23:29:57 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Zhejiang Shenghua Biok Biology Co., Ltd and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Zhejiang Shenghua Biok Biology Co., Ltd (600226). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Zhejiang Shenghua Biok Biology Co., Ltd investor.
Report Summary: Zhejiang Shenghua Biok Biology Co., Ltd is an average quality company with a neutral outlook. Zhejiang Shenghua Biok Biology Co., Ltd has weak business growth and is run by passable management. The trend in Zhejiang Shenghua Biok Biology Co., Ltd fair value exchange rate against its closest rated-competitor, Wuhan Double Co.,Ltd, has been appreciating over the past 2 weeks. When compared to its closest competitor, Zhejiang Shenghua Biok Biology Co., Ltd shows less undervaluation
and is equally likely to outperform the market.
The 3-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Zhejiang Shenghua Biok Biology Co., Ltd for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.